No coin nor oath required. For personal study only.
for the nine months of 2006 was $138.4 M, or $1.43/ share. Net sales for nine months of 2007 were $1.74 bn ($1.78 bn in nine months of 2006). Catalysts recorded net sales for 3Q 2007 of $216.4 M, a nominal decrease versus 3Q 2006, due primarily to lower volumes in HPC refinery catalysts, partially offset by improved pricing in FCC refinery catalysts and polyolefin catalysts. R&D expenses increased $3.9 M to $15.422 M for 3Q 2007 ($11.549 M in 3Q 2006).
๐ SIMILAR VOLUMES
uses for which include bioethanol production, performing particularly well and rapidly catching up with the company's most important product, washing product enzymes. Turnover was up 20% for technical enzymes in 1Q 2007, with surprisingly good sales of enzymes for bioethanol production on the US mar
sales (excluding precious metals) of ยฃ206 M (ยฃ236 M), and underlying operating profit of ยฃ49.2 M (ยฃ76.7 M). There is discussion of the business, including: platinum, palladium, rhodium, and catalysts.